According to a new study published in the prestigious magazine Nature, a personal vaccine, named Autogen Kevumeran, is showing promising results for treating pancreatic cancer, one of the most deadly distortions.

The approach uses the Messenger RNA technique to create a therapeutic cancer vaccine, which shows the ability to stimulate the immune system and probably reduce the risk of the disease that comes back after surgery.

A medical cancer vaccine is a type of treatment designed to identify the immune system and help fight existing cancer. Unlike preventive vaccines (such as HPV vaccine, which protects from cancer), medical vaccines are given to those who already have cancer.

These vaccines work by stimulating the body’s immune response against cancer cells, often by training immune cells (eg T cells) to target specific tumors.

Some therapeutic cancer vaccines are individual, in this way, which means they are made using a patient’s cancer cells or antigens.

Published in Peer-Ruined Journal Nature, Dr. The study led by Vinod Balachandran provides new hope for patients suffering from the most deadly cancer.

Step 1 Results from Clinical Testing

Step 1 Clinical Testing consisted of 16 patients and showed that the vaccine can activate tumor-specific immune cells.

Remandable, these immune cells remained in the body for about four years in some patients. The study showed that patients who had an immune response on vaccines had reduced the risk of their return of cancer after three years, compared to which the immune system did not respond.

Dr. Balachandran, who is a pancreatic cancer surgeon-scientist in the Memorial Slone Catering Cancer, expressed optimism of conclusions.

“The latest data of phase 1 test are encouraging,” he said, “he said,” he suggests that this investigative mRNA vaccine can gather anti-tumor T cells that can recognize pancreatic cancer as foreign, potentially after vaccination. “

New hope for pancreatic cancer treatment

In pancreatic cancer is one of the lowest survival rates among cancer, with only 13% of patients alive five years after diagnosis.

Current remedies such as chemotherapy, radiation and targeted treatments have limited effectiveness against this aggressive disease, which requires immediate new treatments.

The vaccine, autogen kevumeran, was individual for each patient based on unique mutation in his tumor.

This customized approach can train the immune system to identify and attack cancer cells, many such as how to work against vaccine virus.

Medical cancer vaccines, such as Autogen Kevumeran, are designed to treat cancer rather than preventing it. These vaccine proteins provide, called neaulture, which are unique to cancer cells, teach the immune system to identify and attack these cells.

Dr. Balachandran explains, “For pancreatic cancer patients, our latest results support the approach to using individual MRNA vaccines to target the new caste in each patient’s tumor. If you can do this cancer, theoretically, you can be able to develop medical vaccines for other cancer.”

Step 1 test also showed that vaccine-relieved T cells maintained their anti-cancer activity even after patients passed through chemotherapy.

Researchers were concerned that chemotherapy could weaken the effects of the vaccine, but this small study did not support that concern.

Step 2 Clinical Testing will study the effects and safety of autogene kevameran on a large patient group.

“Given our phase 1 test data, we are excited to evaluate medical mRNA cancer vaccines in more pancreatic cancer patients,” Dr. Balachandran said.

The promising consequences of this study hopes to pancreatic cancer patients and highlight the ability of individual MRNA vaccines in treating this challenging disease.